ジクロフェナク皮膚適用製剤の各剤形における局所性副作用の発現傾向に関する研究

抄録

We examined the tendencies of topical adverse effects caused by different dermatological formulations of diclofenac based on the results of our previous study. In patients with adverse effects expressed by gel (n = 64) and tape formulation (n = 174), the most common adverse effect was contact dermatitis, accounting for 59.1% and 80.0%, respectively. The peak month of adverse effects of the gel group was in May, and the peak month of adverse effects of the tape group was in August. We divided the subjects into two groups: elderly and young people and investigated the number of adverse effects and the relative incidence of adverse effects for each group. As a result, the incidence of the young people in the gel group was extremely high in March. In the elderly group, the adverse effects peaked in May, which suggests that they contribute to the peak of the total adverse effects in the gel group through the year. On the other hand, the incidence in the elderly group is higher than that in the young group in each month, and the peaks of incidence were in August and December in the tape group. In both the elderly and young groups, the peak of incidence by tape formulation was in August and the difference between the two groups was remarkable in December. In view of these results, the topical adverse effects of non-steroidal anti-inflammatory drug dermatological formulations could be reduced by the pharmacist providing suitable advice on medications considering the season and patient background, such as age.